Compumedics Limited · ASX:CMP
Compumedics — Non-Deal Roadshow (December 2009)
20 slides from Compumedics's roadshow presentation, Dec 10, 2009
Slide 1: December 2009 Road-show and fund manager presentation
ASX / MEDIA RELEASE For personal use only Melbourne, Australia, Thursday 10th December 2009 December 2009 Road-show and fund manager presentation Leading Australia-based medical-devices company, Compumedics Limited (ASX: CMP) is pleased to provide the attached presentation currently being used in me
Slide 2: About Compumedics
About Compumedics For personal use only Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific’s first fully computerised sleep laboratory. Com
Slide 3: Corporate Overview: Who is Compumedics?
G COMPUMEDICS Compumedics Limited Rig Corporate Overview December 2009 CS Who is Compumedics? COMPUMEDICS Compumedics is a world leading developer, manufacturer and supplier of medical technology and devices to diagnose sleep and neurological disorders and monitor brain function and brain blood flow
Slide 4: Global reach and strategic drivers
Cc Global reach + Corporate headquarters in Melbourne, Australia + Sales, marketing and support offices in — Charlotte, NC. USA — Hamburg, Germany — Singen, Germany + Network of more than 30 distributors globally Strategic drivers + Home sleep testing (HST) - Expansion of Compumedics’ key sleep diag
Slide 5: A brief chronology
CG A brief chronology 1987 Compumedics established Asia Pacific's first fully computerised sleep laboratory 1994 Compumedics wins contracts to supply International Space Station and Space Shuttle flight preparation. 1995 the Company was selected to supply equipment to the US Sleep Heart Health Study
Slide 6: Financials: Business and territory splits
G Financials: Business and territory splits =$40m annual revenues % split by: Business Area Geographic territory OSleep diagnsotics WBrain research USA MEurope BAsia Australia Neuro diagnostics G Ultrasonic blood flow Supplies and technical support Financials: Revenues and bank debt Financial consol
Slide 7: Financials: EBITDA
CG Financials: EBITDA COMPUMEDIC Compumedics - Earnings before interest, tax, depreciation and amortisation (EBITDA) as reported and without Medical Innovation Division R&D spending G0) Foe ra } Pear J 8 esronwom 42 9) 13 2 3 40 ‘ao 30 2 ov “ 19 3s ie: 2 ™ 6 —— A 4 A x E 2 XN a "0 we 2 2005 2007 200
Slide 8: A business snap-shot since listing
CG A business snap-shot since listing + 1999 - Private company with turnover of $9m pa with 45 staff (1 US based) + Listed on ASX (December 2000) ~ raised $11m (post costs/debt) * April 2002 purchased US based Neuroscan — worlds’ leading brain source localisation software — Compumedics turnover $34m
Slide 9: The business: Past, present and future
CS The business: Past, present and future % 2 The past, present and future revenue percentage profiles of the eS business by market/product offering a SS: $150m+ x 7 eed at By 2014 + Expansion of the existing sleep diagnostic business through the HST opportunity in the USA. + Expansion of the sleep
Slide 10: Home sleep testing (HST) USA
Home sleep testing (HST) USA + Approved by Medicare and allowed for with all major insurers + Large undiagnosed market potential — up to 20% of US population said to suffer from sleep apnea + Compumedics has over 1,500 installed beds of sleep diagnostic equipment in the US to leverage off + Majority
Slide 11: Sleep treatment and European market expansion
CG Sleep treatment + Compumedics introduces its first device for the sleep-treatment market, SomniLink® SPAP® + Sleep-treatment market is up to 10 times the size of the global sleep diagnostic market at approximately USD2bn pa + Compumedics has over 4,000 beds of sleep diagnostic equipment world wid
Slide 12: Neurological diagnostics and LTM
Neurological diagnostics and LTM + Existing world market - NEW product, NEW market opportunity for FF Compumedics ‘2 | + Specific LTM global market similar in IN size to sleep diagnostics at Zi i USD220m pa + Expect to replicate market penetration in LTM similar to sleep diagnostics — that is a $10m
Slide 13: Core products: Sleep
Ce Core products: Sleep - Siesta® 802 World leading portable diagnostic device with wireless capability for both sleep and general patient monitoring ’ as Sleep ie Somté® PSG The simplest and most convenient way to meet requirements for full PSG ... absolutely anywhere. Sy: n > Full PSG ambulatory r
Slide 14: Core products: Sleep
mM Core products: Sleep E-Series Laboratory based diagnostic product for both full polysomnography (PSG) “sleep” studies and or separate EEG studies. First to be "Network-Ready” Core products: Sleep S) profes ProFusion PSG 3 A high-powered comprehensive software companion to our family of leading-ed
Slide 15: Core products: Neuro diagnostics
Ce Core products: Neuro diagnostics or ‘SN | | NEW !! Neuvo® LTM i The state of the art | a technology platform from Compumedics for Long term EEG monitoring. = Bedside display = Up to 256 channels = Single connection = Touch-screen monitor = Wall or Mobile configuration ~ I ™ Ce Core products: Neur
Slide 16: Core products: Neuro diagnostics and brain monitoring
“ Core products: Neuro diagnostics profusion ; CEG ProFusion EEG4 Next generation clinical LTM software package that offers unprecedented ease of use in the EEG lab, and in post-recording analysis and review I ™ Néiifoscience Core products: Brain monitoring Curry® 6 Offers extensive possibilities fo
Slide 17: Core products: Brain monitoring
Core products: Brain monitoring Source Offers impressive source localisation capabilities, including several dipole models and three spheres, BEM and FEM reconstructions. Stim Presents audio and video stimuli and sends stimuli and response to Scan NY where they are *, incorporated into >, c™» ws the
Slide 18: Core products: Ultrasonic blood flow
Cc Core products: Ultrasonic blood flow > * + Doppler Box = Unique fully digital Doppler M-Mode = “Depth of Flow’ Display = - «= Size and weight of a “pencil box" % = Modular * - Attachable to any PC - *Soft” upgrade to any/all Special Function Tests Emboli Detection Emboli Discrimination Vasomotor
Slide 19: Driving growth and key opportunities
G Driving growth and key opportunities Continue organic growth or consider capital raising and accelerated growth for: — New HST market opportunity — European market expansion — New LTM (Neuvo®) market opportunity — New sleep-treatment (SomniLink® SPAP®) market opportunity (strategies for sleep-trea
Slide 20: For personal use only
AjUO SSN feuUOSsiJed JOS